Gyre Therapeutics, Inc. (NASDAQ:GYRE) Short Interest Update

Gyre Therapeutics, Inc. (NASDAQ:GYRE) was the target of a significant drop in short interest in the month of October. As of October 31st, there was short interest totalling 376,600 shares, a drop of 16.1% from the October 15th total of 448,700 shares. Currently, 1.6% of the company’s shares are short sold. Based on an average daily volume of 48,100 shares, the short-interest ratio is presently 7.8 days.

Hedge Funds Weigh In On Gyre Therapeutics

Institutional investors have recently made changes to their positions in the company. Rhumbline Advisers purchased a new position in shares of Gyre Therapeutics during the second quarter valued at $123,000. Renaissance Technologies LLC purchased a new position in shares of Gyre Therapeutics during the second quarter valued at $166,000. WINTON GROUP Ltd purchased a new position in shares of Gyre Therapeutics during the second quarter valued at $220,000. Bank of New York Mellon Corp purchased a new position in shares of Gyre Therapeutics during the second quarter valued at $218,000. Finally, Barclays PLC increased its stake in shares of Gyre Therapeutics by 281.8% during the third quarter. Barclays PLC now owns 9,288 shares of the company’s stock valued at $116,000 after buying an additional 6,855 shares during the period. Hedge funds and other institutional investors own 23.99% of the company’s stock.

Gyre Therapeutics Trading Down 5.2 %

GYRE stock opened at $13.12 on Monday. The business’s fifty day simple moving average is $13.83 and its two-hundred day simple moving average is $12.98. Gyre Therapeutics has a twelve month low of $8.26 and a twelve month high of $30.40.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.